With the decreasing virulence of omicrons strain, the current domestic epidemicprevention policy has been changed based on the health of the people and the developmentneeds of the country. At present, the infection rate of the novel coronavirus in China isrising rapidly. Previous studies have found that patients with chronic liver disease aremore likely to be co-infected with coronavirus disease 2019 and have a worse prognosis.Based on its unique immune mechanism and therapeutic drugs, patients with autoimmuneliver disease also have very different manifestations after infection with the novelcoronavirus. By observing the clinical characteristics and prognosis of patients withautoimmune liver disease complicated with coronavirus disease 2019, this study analyzedthe roles of vaccines, immunosuppressive agents and ursodeoxycholic acid , and exploredthe immune mechanism behind them, so as to seek new anti-coronavirus disease 2019 drugsand provide new strategies for clinical prevention and treatment.
Not Provided
Other: Different types of disease
Groups were observed according to disease type
Group A: 1) Aged 18-75; 2) AIH patients diagnosed by AIH comprehensive scoring diagnosis
system; 3) No history of other malignant tumors; 4) No metabolic diseases such as
hypertension and diabetes; 5) No serious circulatory and respiratory diseases; 6)
Non-alcoholic liver disease, drug-induced hepatitis, viral hepatitis and other liver
diseases; 7) Exclude pregnant and lactating women.
Group B: 1) Aged 18-75 years; 2) Patients with PBC diagnosis; 3) No history of other
malignant tumors; 4) No metabolic diseases such as hypertension and diabetes; 5) No
serious circulatory and respiratory diseases; 6) Non-alcoholic liver disease,
drug-induced hepatitis, viral hepatitis and other liver diseases; 7) Exclude pregnant and
lactating women.
Group B: 1) Aged 18-75 years; 2) Patients with PBC diagnosis; 3) No history of other
malignant tumors; 4) No metabolic diseases such as hypertension and diabetes; 5) No
serious circulatory and respiratory diseases; 6) Non-alcoholic liver disease,
drug-induced hepatitis, viral hepatitis and other liver diseases; 7) Exclude pregnant and
lactating women.
Group B: 1) Aged 18-75 years; 2) Patients with PBC diagnosis; 3) No history of other
malignant tumors; 4) No metabolic diseases such as hypertension and diabetes; 5) No
serious circulatory and respiratory diseases; 6) Non-alcoholic liver disease,
drug-induced hepatitis, viral hepatitis and other liver diseases; 7) Exclude pregnant and
lactating women.
Group E: Those who had no previous history of COVID-19 infection and had been vaccinated
against COVID-19.
-
-
Dazhi Zhang
Chongqing, Chongqing, China
Not Provided